What are the pharmacokinetics of phentolamine (bioavailability, hepatic metabolism, elimination pathways)?

The provided materials do not contain data on bioavailability, hepatic metabolism, or elimination pathways of phentolamine. It is noted that the duration of action is short: 10–15 minutes upon intravenous administration. The brief action is due to excess norepinephrine (released as a result of presynaptic $\alpha_2$-receptor blockade) competitively displacing phentolamine from postsynaptic $\alpha_1$-receptors. Oral formulations require administration 3–4 times daily.

In what doses and how frequently is phentolamine administered to manage a hypertensive crisis in pheochromocytoma?

The provided materials do not contain precise data on specific doses or dosing frequency of phentolamine for managing a hypertensive crisis in pheochromocytoma. It is only known that phentolamine and phenoxybenzamine are used in pheochromocytoma, and that phentolamine is used before and during surgery to prevent and treat hypertensive crises.

What happens if epinephrine is administered in the presence of phentolamine?

Blood pressure will drop sharply rather than rise. This occurs because vasoconstrictive $\alpha$-receptors are blocked by phentolamine, allowing epinephrine to act exclusively on $\beta_2$-receptors, which mediate vasodilation.

Why do phentolamine injections cause diarrhea and urinary frequency?

This is a consequence of parasympathetic nervous system stimulation. The drug blocks presynaptic $\alpha_2$-receptors, which enhances acetylcholine release from postganglionic nerve terminals, stimulating GI motility and decreasing bladder sphincter tone.

How can orthostatic hypotension be prevented after injection?

Because the drug dilates veins and inhibits venoconstriction, blood pools in the lower body upon assuming an upright position. To prevent syncope, the patient should remain in a supine position for 1–2 hours after administration.

Home › Pharmacology › Non-Selective Alpha-Blockers

Non-Selective Alpha-Blockers

Phentolaminum, Phenoxybenzaminum

For medical students2 min readUpdated 2026-10-10

A class of pharmacological agents that impair transmission in adrenergic synapses by directly blocking both $\alpha_1$ and $\alpha_2$-adrenergic receptors. Their administration prevents the interaction of these receptors with endogenous norepinephrine and circulating epinephrine, leading to marked vasodilation.

Prototype DrugPhentolamine is a short-acting, competitive receptor blocker.

Ultra-Long DurationPhenoxybenzamine binds irreversibly and acts for more than 48 hours.

Cardiac EffectCause pronounced tachycardia due to presynaptic receptor blockade.

Primary IndicationManagement of hypertensive crises in pheochromocytoma.

Drug Classification

Non-selective $\alpha_1, \alpha_2$-adrenergic blockers are divided by origin into two main subgroups:

Synthetic agents. These include the imidazoline derivative phentolamine and the long-acting agent phenoxybenzamine.
Ergot alkaloid derivatives. This subgroup includes dihydroergotamine and nicergoline.

Pharmacodynamics of Phentolamine

Phentolamine serves as the key prototype drug of the group. It competitively blocks postsynaptic $\alpha_1$-adrenergic receptors, as well as all types of $\alpha_2$-adrenergic receptors, including presynaptic ones.

Hemodynamic and Metabolic Effects:

Blood Pressure Reduction. Blockade of vascular wall receptors causes sustained vasodilation, lowering both arterial and venous pressure.
Tachycardia. Has a dual origin: a reflex response to hypotension and a direct consequence of presynaptic $\alpha_2$-receptor blockade (disruption of negative feedback, release of excess norepinephrine stimulating cardiac $\beta_1$-receptors).
Increased Oxygen Demand. Tachycardia increases myocardial oxygen demand.
Enhanced Renin Secretion.

The action of phentolamine upon intravenous administration lasts only 10–15 minutes. This is because the excess norepinephrine released due to presynaptic blockade rapidly displaces the drug from its receptor binding sites.

Phenoxybenzamine: Characteristics of Long-Term Blockade

In situations requiring prolonged blood pressure control, phenoxybenzamine is used.

Unlike phentolamine, it forms stable covalent bonds with receptors, causing irreversible blockade. Additionally, the drug inhibits neuronal reuptake of the neurotransmitter. Due to this mechanism, the hypotensive effect persists for 48 hours or more. Its side effect profile is similar to that of phentolamine.

Clinical Use

The main indication for non-selective $\alpha$-blockers is pheochromocytoma—a catecholamine-secreting tumor of the adrenal medulla.

The drugs are used to manage crises, as well as to prepare the patient for surgical removal of the tumor (and during surgery itself).
In inoperable cases, the drugs are administered long-term, always in combination with $\beta_1$-blockers to prevent tachycardia.

Other indications include:

Management of hypertensive crises during clonidine withdrawal syndrome and "cheese effect" (tyramine ingestion while taking MAO inhibitors).
Peripheral vascular disorders: Raynaud's disease, thromboangiitis obliterans, frostbite, and trophic ulcers. The drugs dilate arterioles and precapillaries, eliminating tissue hypoxia.

Side Effects and Contraindications

Adrenergic receptor blockade causes several characteristic adverse reactions:

Cardiovascular system: Orthostatic hypotension (potentially leading to syncope upon sudden standing due to blood pooling in veins) and pronounced tachycardia.
Mucous membranes: Nasal congestion due to edema and vasodilation of the nasal mucosa.
Gastrointestinal tract and pelvis: Parasympathetic hyperstimulation. Blockade of presynaptic $\alpha_2$-receptors leads to excessive acetylcholine release, causing diarrhea, hypersalivation, increased gastric secretion, urinary frequency, and ejaculation disorders.

Due to cardiac strain, the drugs are contraindicated in angina pectoris, a history of myocardial infarction, and baseline arterial hypotension.

Frequently asked questions

What are the pharmacokinetics of phentolamine (bioavailability, hepatic metabolism, elimination pathways)?: The provided materials do not contain data on bioavailability, hepatic metabolism, or elimination pathways of phentolamine. It is noted that the duration of action is short: 10–15 minutes upon intravenous administration. The brief action is due to excess norepinephrine (released as a result of presynaptic $\alpha_2$-receptor blockade) competitively displacing phentolamine from postsynaptic $\alpha_1$-receptors. Oral formulations require administration 3–4 times daily.
In what doses and how frequently is phentolamine administered to manage a hypertensive crisis in pheochromocytoma?: The provided materials do not contain precise data on specific doses or dosing frequency of phentolamine for managing a hypertensive crisis in pheochromocytoma. It is only known that phentolamine and phenoxybenzamine are used in pheochromocytoma, and that phentolamine is used before and during surgery to prevent and treat hypertensive crises.
What happens if epinephrine is administered in the presence of phentolamine?: Blood pressure will drop sharply rather than rise. This occurs because vasoconstrictive $\alpha$-receptors are blocked by phentolamine, allowing epinephrine to act exclusively on $\beta_2$-receptors, which mediate vasodilation.
Why do phentolamine injections cause diarrhea and urinary frequency?: This is a consequence of parasympathetic nervous system stimulation. The drug blocks presynaptic $\alpha_2$-receptors, which enhances acetylcholine release from postganglionic nerve terminals, stimulating GI motility and decreasing bladder sphincter tone.
How can orthostatic hypotension be prevented after injection?: Because the drug dilates veins and inhibits venoconstriction, blood pools in the lower body upon assuming an upright position. To prevent syncope, the patient should remain in a supine position for 1–2 hours after administration.

Go deeper

Mechanisms of reversible and irreversible receptor blockade
Sympatholytics: differences from adrenergic blockers
Pharmacodynamics of ergot alkaloids
Tyramine syndrome and clonidine withdrawal syndrome
The role of beta-blockers in combination therapy for pheochromocytoma